TAP Pharmaceutical Products last week pulled the TV portion of campaign for heartburn drug Prevacid “to focus on print media that it hopes will better explain the drug’s potential side effects and health risks,” the company said in a statement. TAP move followed last week’s report that the FDA has cited Bayer Pharmaceuticals, Schering-Plough, GlaxoSmithKline and Pfizer for misleading ads. Lead agency is Interpublic’s Merkley + Partners.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in